William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
View Older Stories View More Recent Stories
-
Vertical Aerospace (EVTL) Launches Proposed $75M Share Offering
-
Vertical Aerospace Announces Launch of Proposed Underwritten Public Offering
-
US car wash operator Spotless Brands explores sale, sources say
-
William Blair Downgrades Charles River Labs (CRL) to Market Perform
-
Karman Announces Filing of Registration Statement for Proposed Initial Public Offering
-
Can Planet Fitness stay competitive after price hike? DA Davidson weighs in
-
William Blair Expands Biopharma Investment Banking Group With Senior Hire
-
Suvoda and Greenphire to Merge Creating a Technology Platform Optimizing Clinical Trial Processes and Streamlining the Patient Journey
-
UniVista Insurance Partners with GRAM to Drive Next Chapter of Growth
-
William Blair and Raymond James give healthcare sector outlook for 2025
-
William Blair Starts CBOE Holdings (CBOE) at Market Perform
-
Aperture Announces Strategic Majority Investment from Genstar Capital
-
William Blair Names Stewart Licudi Head of European Investment Banking
-
Advent International to Acquire Sauer Brands, a Scaled Platform of Leading Condiments & Seasonings Brands
-
William Blair Starts ServiceTitan (TTAN) at Outperform
-
Grant Thornton in the US and Ireland close transformational transaction; create global multidisciplinary platform
-
Quisitive to be Acquired by H.I.G. Capital
-
William Blair Reiterates Market Perform Rating on Amedisys (AMED)
-
William Blair Downgrades Applied Therapeutics (APLT) to Market Perform
-
Guardian Capital Partners Raises Continuation Fund with Barings and Kline Hill Partners to Support Continued Growth of Havis, Inc.
-
ServiceTitan Announces Closing of Underwriters’ Option to Purchase Additional Shares
-
Viad Corp. (VVI) Announces CFO Transition
-
Hostaway Announces $365 Million Strategic Growth Investment Led by General Atlantic
-
Viad Corp Announces CFO Transition
-
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional
-
William Blair Reiterates Market Perform Rating on Under Armour, Inc. (UAA)
-
MSA Safety to Present at the William Blair Public Safety Technology Virtual Conference
-
These 4 Consumer Stocks Are 2025 Top Picks at William Blair
-
ServiceTitan (TTAN) Prices 8.8M Share IPO at $71/sh
-
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
-
ServiceTitan Announces Pricing of Initial Public Offering
-
RAMACO RESOURCES, INC. ANNOUNCES EXERCISE OF UNDERWRITERS' OVER-ALLOTMENT OPTION IN CONNECTION WITH ITS SENIOR UNSECURED NOTES OFFERING
-
Arthur J. Gallagher & Co. Announces Closing of Public Offering of Common Stock
-
Presenting Companies and Schedule Announced for the 2025 ICR Conference
-
William Blair Downgrades Dave & Buster's (PLAY) to Market Perform
-
NewAmsterdam Pharma (NAMS) Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
-
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
-
SOLVD Health to Present at William Blair’s Innovator Series: Life Science Tools and Diagnostics
-
Sponsors Announced for the 2025 ICR Conference
-
Cardiff Oncology (CRDF) Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
-
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
-
Arthur J. Gallagher (AJG) Announces Pricing of $8.5 Billion of Shares of Its Common Stock
-
Arthur J. Gallagher & Co. Announces Pricing of $8.5 Billion of Shares of Its Common Stock
-
William Blair on Underperform Rated Palantir (PLTR), 'the company’s revenue is still tracking to miss management’s 2025 target '
-
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total G
-
Orion Announces Wealthtech Industry Leader Chris Shutler as Head of Strategy
-
Janux Therapeutics (JANX) Prices 5.32M Share Offering at $63/sh
-
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
-
Eagle Point Credit Company Inc. Prices $100 Million Public Offering of Notes
-
Wynnchurch Capital Exits Infra Pipe Solutions

